New modification strategy of matrine as Hsp90 inhibitors based on its specific L conformation for cancer treatment
- Bioorg Med Chem. 2020 Feb 15;28(4):115305. doi: 10.1016/j.bmc.2020.115305.
- 1. Medicinal College, Guangxi University, Nanning 530004, China; School of Chemistry and Chemical Engineering, Guangxi University, Nanning 530004, China.
- 2. School of Chemistry and Chemical Engineering, Guangxi University, Nanning 530004, China.
- 3. Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic Translational Medicine, Xi'an Medical University, Xi'an 710021, China.
- 4. College of Veterinary Medicine, Northwest A&F University, Yangling 712100, China.
- 5. School of Chemistry and Chemical Engineering, Guangxi University, Nanning 530004, China; Department of Chemistry, Sarhad University of Science & Information Technology, Peshawar, Khyber Pakhtunkhwa 25120, Pakistan.
- 6. Medicinal College, Guangxi University, Nanning 530004, China. Electronic address: [email protected].
- 7. Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic Translational Medicine, Xi'an Medical University, Xi'an 710021, China. Electronic address: [email protected].
The similarity of spatial structure between radicicol and matrine urged us to perform conformation modification of matrine, followed by L-shaped matrine derivatives, 6, 12, 21a-h and 22a-h were originally designed, synthesized and evaluated for HSP90N inhibitors as Anticancer agents. TSA (Thermal Shift Assay) results indicated that 21e, 22a-c and 22e-g exhibited strong binding force against HSP90N with∣ΔTm∣ > 3, meanwhile, MTT assay also revealed these compounds displayed potent Anticancer activity with IC50 values below 25 μM against HepG2, HeLa and MDA-MB-231 cells lines. Then, compound 22g with a high ΔTm = 10.92 was chosen as a representative to perform further mechanism study. It can induce cell Apoptosis, arrest the cell cycle at the S phase and decrease the expression level of HSP90 in Hela cell. These results originally provided targeted modification strategy for matrine derivatives to serve as HSP90 inhibitors for Cancer therapy.
-
Cat. No.Product NameDescriptionTargetResearch Area
-